Regeneron Pharmaceuticals, Inc.
MX ˙ BMV ˙ US75886F1075
SecurityMX:REGN / Regeneron Pharmaceuticals, Inc.
InstitutionDanske Bank A/s
Latest Disclosed Ownership107,220 shares
Latest Disclosed Value $ 82,842,461
Danske Bank A/s reports 7.97% increase in ownership of REGN / Regeneron Pharmaceuticals, Inc.

On May 12, 2026 - Danske Bank A/s filed a 13F-HR form disclosing ownership of 107,220 shares of Regeneron Pharmaceuticals, Inc. (MX:REGN) valued at $82,842,461 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 99,302 shares of Regeneron Pharmaceuticals, Inc.. This represents a change in shares of 7.97% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-12 2026-03-31 13F Regeneron Pharmaceuticals COM 75886F107 107,220 7,918 7.97 82,842 8.08 0.0938
2026-02-02 2025-12-31 13F Regeneron Pharmaceuticals COM 75886F107 99,302 43,775 78.84 76,648 145.50 0.1783
2025-11-19 2025-09-30 13F/A-1 Regeneron Pharmaceuticals COM 75886F107 55,527 4,865 9.60 31,221 17.39 0.0776
2025-11-13 2025-09-30 13F Regeneron Pharmaceuticals COM 75886F107 607 607 341 0.0175
2025-12-18 2025-06-30 13F Regeneron Pharmaceuticals COM 75886F107 50,662 -12,648 -19.98 26,598 -33.76 0.0661
2025-12-18 2025-03-31 13F Regeneron Pharmaceuticals COM 75886F107 63,310 3,216 5.35 40,153 -6.20 0.1227
2026-03-18 2024-12-31 13F Regeneron Pharmaceuticals COM 75886F107 60,094 -8,923 -12.93 42,807 -41.00 0.1280
2026-03-18 2024-09-30 13F Regeneron Pharmaceuticals COM 75886F107 69,017 1,337 1.98 72,553 2.00 0.2417
2026-03-18 2024-06-30 13F Regeneron Pharmaceuticals COM 75886F107 67,680 13,502 24.92 71,134 36.41 0.2625
2026-03-18 2024-03-31 13F Regeneron Pharmaceuticals COM 75886F107 54,178 54,178 52,146 0.1636
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.